Sodium-glucose cotransporter 2 inhibitors have demonstrated substantial cardiovascular and renal benefits in adults, including reduced heart failure events across diabetic and nondiabetic populations. However, pediatric cardiac data remain limited, and real-wo... ...

请注册登录后继续浏览